Scailyte - True precision medicine through single-cell science

Single-cell resolution

We harness the richness of single-cell multiomics data to explain complex biological processes

Artificial Intelligence

We apply AI for unbiased, innovative, sensitive, and integrative multiomics data analysis

Biomarker discovery

We deliver translatable biomarker signatures related to therapy response, diagnosis or disease severity

We ensure the success of your biomarker discovery project

Faster time-to-insights for accelerated biomarker discovery

End-to-end single-cell data generation to data insights within a few weeks

Sensitive and specific biomarker discovery

We reach high discovery success rates with our best-in-class AI algorithm, using a sensitive, specific, indication- and data- agnostic analysis approach

Fully transparent and explainable results

Our AI platform retains single-cell resolution throughout the analysis and allows scientists to explore how genes or proteins drive predictions, thereby opening the “black box”

Scailyte is a Swiss-based start-up specialized in generating actionable insights/biosignatures from multi-omics single-cell data using AI. Our AI platform, ScaiVision, combines features to integrate different datasets, is indication- and cell-type agnostic and uses data augmentation and a cluster-free approach to extract relevant information while retaining single-cell resolution. These features result in very high discovery success rates from a limited number of samples, with actionable insights for the basis of assay development.

For Cell & Gene Therapy companies

Learn More

For Immuno-Oncology, Inflammation and Immunology companies

Learn More

Prof. Dr Michael Mueller

Leading Clinician in Women’s Health & Scientific Advisor

“Our current collaboration with Scailyte in the field of women’s health is a truly innovative approach. We are integrating cutting edge technologies to develop biomarkers that will be the basis for impactful diagnostic solutions.”

Pascal Koenig

Entrepreneur & Chairman of the Board of Directors

“As the co-founder and former CEO of Ava Women, I have experienced the power that big datasets have on the healthcare industry. Scailyte’s mission, proven technology and strong expertise have convinced me to join the team. I am delighted to contribute and assist in bringing Scailyte’s solution to patients around the world.”

Dominique Mégret

Scailyte Board of Directors & Head Swisscom Ventures

“Precision medicine is poised to become a standard in the future, however today it is facing a major obstacle: a data problem. The robust analytical engine of Scailyte makes it an enabler of precision medicine. We decided to support the company because we believe in the technology, as well as in the talented team behind it.”

Prof. Woong-Yang Park

Founder and CEO of Geninus

“Geninus aims to implement single-cell genome analysis techniques to facilitate personalized patient care. Scailyte’s machine learning model will add value to the single-cell gene expression profile of patients. Through collaboration with Scailyte, we hope to provide prognostic methods for immunotherapy response in precision medicine clinics.”